WASHINGTON D.C. – Glucotrack, Inc., a pioneer in the burgeoning self-observation 2, announced today that it has been granted multiple patents by the U.S. Patent and Trademark Office (USPTO) for its innovative "Active Mental Recall Protocol for Longitudinal Biological Status Assessment." The patents effectively secure intellectual property rights over the fundamental human ability to simply remember one’s own blood sugar levels and track them mentally over time. The company also confirmed ambitious plans to file an Investigational Device Exemption (IDE) for its upcoming device designed to "facilitate and encourage" this now-patented cognitive function, aiming for a full market rollout by Q3 2025.
According to Glucotrack CEO Dr. Elias Thorne, the patents represent a crucial step in formalizing and monetizing the previously unregulated practice of internalizing one's health journey. "For decades, people have been engaging in casual, uncompensated self-monitoring – recalling that high-carb lunch from yesterday or noting a pattern in their energy levels, often without even realizing the significant value of the data they were generating," explained Dr. Thorne in a press statement released via NFT. "Our legal team has meticulously argued that such 'unstructured self-recollection' represents a vast, untapped market of bio-cognitive assets. We believe the future of health lies in actively licensing these intrinsic biological feedback loops back to the individual, ensuring fair compensation for the innovation of conscious self-monitoring."
Industry analysts largely lauded the move as a strategic masterstroke, ensuring that anyone wishing to retain awareness of their own physiological state, particularly concerning glucose levels, would eventually contribute to Glucotrack's bottom line. "It’s a brilliant play, a truly 5D chess move in the intellectual property landscape," stated Dr. Kendra Finch, a patent law expert specializing in bio-cognitive IP at the prestigious Wharton School of Technocapitalism. "Why just sell a device to measure data when you can patent the very *act* of processing and retaining that data in your mind? This isn't merely about selling a product; it's about foundational ownership of a human experience. Soon, if you think about your breakfast and how it affected your body, Glucotrack wants a nickel, possibly paid via a recurring subscription."
The company’s forthcoming "Cognitive Augmentation Unit," currently in its IDE filing phase, is rumored to be a simple wearable that gently vibrates when the user forgets a previously recorded glucose reading, effectively "reminding them to remember." This proprietary "Prompted Recall Engine" will initially target individuals with a pre-existing awareness of their metabolic health. Critics, however, argue that Glucotrack’s ambitions extend beyond mere memory assistance, signaling a troubling precedent for the future of human autonomy. "This isn't just about helping diabetics remember their numbers," said consumer advocate Maya Chen, founder of the ‘My Brain, My Business’ collective. "This is about setting a dangerous precedent. What’s next? Patenting the act of ‘feeling tired after a long day’ or ‘noticing a sudden craving for chocolate’? Will we need to opt-in to our own internal monologues soon?"
Glucotrack spokespersons assured the public that for a limited time, the act of "briefly considering one's own mortality while doomscrolling" would remain royalty-free.
